Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38354228)

  • 1. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.
    Chen J; Laverty DJ; Talele S; Bale A; Carlson BL; Porath KA; Bakken KK; Burgenske DM; Decker PA; Vaubel RA; Eckel-Passow JE; Bhargava R; Lou Z; Hamerlik P; Harley B; Elmquist WF; Nagel ZD; Gupta SK; Sarkaria JN
    Sci Transl Med; 2024 Feb; 16(734):eadj5962. PubMed ID: 38354228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR Screen of Druggable Targets in Small Cell Lung Cancer Identified ATM Inhibitor (AZD1390) as a Radiosensitizer.
    Ran X; Wu BX; Shi M; Song L; Nixon K; Philip V; He HH; Tsao MS; Lok BH
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1308-1314. PubMed ID: 38104868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
    Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
    Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma.
    Xie J; Kuriakose T; Bianski B; Twarog N; Savage E; Xu K; Zhu X; He C; Hansen B; Wang H; High A; Li Y; Rehg JE; Tillman HS; Freeman BB; Rankovic Z; Onar-Thomas A; Fan Y; Wu G; Peng J; Miller S; Baker SJ; Shelat AA; Tinkle CL
    Neuro Oncol; 2023 Oct; 25(10):1828-1841. PubMed ID: 36971093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury.
    Lan Z; Qu LJ; Liang Y; Chen LQ; Xu S; Ge JW; Xue ZW; Bao XY; Xia SN; Yang HY; Huang J; Xu Y; Zhu XL
    CNS Neurosci Ther; 2024 Apr; 30(4):e14696. PubMed ID: 38668740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors.
    Talele S; Zhang W; Chen J; Gupta SK; Burgenske DM; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2022 Oct; 383(1):91-102. PubMed ID: 36137710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation.
    Blake SM; Stricker SH; Halavach H; Poetsch AR; Cresswell G; Kelly G; Kanu N; Marino S; Luscombe NM; Pollard SM; Behrens A
    Elife; 2016 Mar; 5():. PubMed ID: 26984279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
    Biddlestone-Thorpe L; Sajjad M; Rosenberg E; Beckta JM; Valerie NC; Tokarz M; Adams BR; Wagner AF; Khalil A; Gilfor D; Golding SE; Deb S; Temesi DG; Lau A; O'Connor MJ; Choe KS; Parada LF; Lim SK; Mukhopadhyay ND; Valerie K
    Clin Cancer Res; 2013 Jun; 19(12):3189-200. PubMed ID: 23620409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner.
    Palanichamy K; Patel D; Jacob JR; Litzenberg KT; Gordon N; Acus K; Noda SE; Chakravarti A
    Mol Cancer Ther; 2018 Feb; 17(2):336-346. PubMed ID: 28838997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390.
    Pike KG; Hunt TA; Barlaam B; Benstead D; Cadogan E; Chen K; Cook CR; Colclough N; Deng C; Durant ST; Eatherton A; Goldberg K; Johnström P; Liu L; Liu Z; Nissink JWM; Pang C; Pass M; Robb GR; Roberts C; Schou M; Steward O; Sykes A; Yan Y; Zhai B; Zheng L
    J Med Chem; 2024 Feb; 67(4):3090-3111. PubMed ID: 38306388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines.
    Godoy PR; Mello SS; Magalhães DA; Donaires FS; Nicolucci P; Donadi EA; Passos GA; Sakamoto-Hojo ET
    Mutat Res; 2013 Aug; 756(1-2):46-55. PubMed ID: 23817105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.
    Sharma S; Munger K
    mBio; 2020 Jun; 11(3):. PubMed ID: 32546626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis.
    Tew BY; Kalfa AJ; Yang Z; Hurth KM; Simon T; Abnoosian E; Durant ST; Hamerlik P; Salhia B
    Clin Cancer Res; 2023 Nov; 29(21):4492-4503. PubMed ID: 37585496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATM in DNA repair in cancer.
    Jin MH; Oh DY
    Pharmacol Ther; 2019 Nov; 203():107391. PubMed ID: 31299316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.
    Jucaite A; Stenkrona P; Cselényi Z; De Vita S; Buil-Bruna N; Varnäs K; Savage A; Varrone A; Johnström P; Schou M; Davison C; Sykes A; Pilla Reddy V; Hoch M; Vazquez-Romero A; Moein MM; Halldin C; Merchant MS; Pass M; Farde L
    Neuro Oncol; 2021 Apr; 23(4):687-696. PubMed ID: 33123736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture.
    Tribius S; Pidel A; Casper D
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):511-23. PubMed ID: 11380241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
    Golding SE; Rosenberg E; Adams BR; Wignarajah S; Beckta JM; O'Connor MJ; Valerie K
    Cell Cycle; 2012 Mar; 11(6):1167-73. PubMed ID: 22370485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.